Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Kristen, Picha"'
Autor:
Edwin T Parlevliet, Yanan Wang, Janine J Geerling, Janny P Schröder-Van der Elst, Kristen Picha, Karyn O'Neil, Vedrana Stojanovic-Susulic, Tatiana Ort, Louis M Havekes, Johannes A Romijn, Hanno Pijl, Patrick C N Rensen
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49152 (2012)
ObjectiveIn addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on v
Externí odkaz:
https://doaj.org/article/22f65b1129434deb817148c89ddabf95
Autor:
Xiaolin He, Bing Han, Marco Mura, Li Li, Marcelo Cypel, Avery Soderman, Kristen Picha, Jing Yang, Mingyao Liu
Publikováno v:
PLoS ONE, Vol 3, Iss 1, p e1527 (2008)
BACKGROUND: Interaction between the coagulation and inflammation systems plays an important role in the development of acute respiratory distress syndrome (ARDS). Anti-coagulation is an attractive option for ARDS treatment, and this has promoted deve
Externí odkaz:
https://doaj.org/article/18ca8028ed7d49279386c1952d9377cf
Autor:
Olivier Bénichou, Wolfgang Wirth, Jennifer H. Lee, Robert J. Buck, Susanne Maschek, Richard Davies, Felix Eckstein, Alberto Gimona, Kristen Picha, Martin Hudelmaier, M.-P. H. Le Graverand, Michael C. Nevitt, D. Dreher
Publikováno v:
Osteoarthritis and Cartilage. 19(6):689-699
Summary Objective The sensitivity to change of quantitative analysis of cartilage in knee osteoarthritis using magnetic resonance imaging (MRI) is compromised by the spatial heterogeneity of cartilage loss. We explore whether extended (medial–later
Autor:
Subinay Ganguly, Qing Mike Tang, Allen Magill, Jennifer F. Nemeth, Haimanti Dorai, Kristen Picha, Karyn T. O'Neil, T. Shantha Raju, Gordon Moore, Erwin Cammaart, Yonghui Wang, Michael J. Lewis
Publikováno v:
Biotechnology and Bioengineering. 103:162-176
In an attempt to develop a high producing mammalian cell line expressing CNTO736, a Glucagon like peptide-1-antibody fusion protein (also known as a Glucagon like peptide-1 MIMETIBODY), we have noted that the N-terminal GLP-1 portion of the MIMETIBOD
Autor:
Mark Cunningham, Vedrana Stojanovic-Susulic, Karyn T. O'Neil, Daniel J. Drucker, Kristen Picha, Ashok Mathur, Tracy Spinka-Doms, Beth Ann Thomas, Tatiana Ort, Michael Scully, Avery Soderman
Publikováno v:
Diabetes
OBJECTIVE—We have developed a novel platform for display and delivery of bioactive peptides that links the biological properties of the peptide to the pharmacokinetic properties of an antibody. Peptides engineered in the MIMETIBODY platform have im
Autor:
Marian T. Nakada, Tam Susan H, Cam Ngo, Hillary Millar, Kristen Picha, G. Mark Anderson, Francis L. McCabe, Richard Tawadros
Publikováno v:
International Journal of Cancer. 120:1261-1267
Thromboembolic complications are frequently associated with advanced cancer. Interestingly, one of the major initiators of blood coagulation, tissue factor (TF), is reported to be overexpressed in several tumor types and can be found on both tumor ce
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 1088
The MIMETIBODY™ platform was developed to expand the opportunities for application of biotherapeutics. While the utility of antibodies as antagonists has been well demonstrated, their application as agonists has been more challenging. For steric re
Publikováno v:
Methods in Molecular Biology ISBN: 9781627036726
The MIMETIBODY™ platform was developed to expand the opportunities for application of biotherapeutics. While the utility of antibodies as antagonists has been well demonstrated, their application as agonists has been more challenging. For steric re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::465ea8c58f393cb1e9a6fa6421c4df98
https://doi.org/10.1007/978-1-62703-673-3_9
https://doi.org/10.1007/978-1-62703-673-3_9
Publikováno v:
Inflammationallergy drug targets. 12(2)
Inhaled therapeutics are used routinely to treat a variety of pulmonary diseases including asthma, COPD and cystic fibrosis. In addition, biological therapies represent the fastest growing segment of approved pharmaceuticals. However, despite the inc
Autor:
Karyn O'neil, Vedrana Stojanovic-Susulic, Janine J. Geerling, Kristen Picha, Patrick C.N. Rensen, Janny P. Schröder-van der Elst, Louis M. Havekes, Edwin T. Parlevliet, Tatiana Ort, Hanno Pijl, Johannes A. Romijn, Yanan Wang
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49152 (2012)
PLoS ONE, 11, 7
PLoS ONE, 7(11)
PLoS ONE
PLoS ONE, 11, 7
PLoS ONE, 7(11)
PLoS ONE
Objective: In addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on